Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low - What's Next?

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $29.51 and last traded at $30.22, with a volume of 859554 shares. The stock had previously closed at $30.64.

Analyst Ratings Changes

Several analysts have commented on JANX shares. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reissued an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Leerink Partners increased their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $92.44.

Janux Therapeutics Stock Down 2.1 %

The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -26.22 and a beta of 3.23. The stock's fifty day moving average is $39.47 and its 200-day moving average is $47.06.

Remove Ads

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 5,000 shares of the company's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares of the company's stock, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,002 shares of company stock valued at $2,684,703 in the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Plato Investment Management Ltd boosted its stake in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Janux Therapeutics during the fourth quarter worth $59,000. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $139,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth $159,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.